questionsmedicales.fr
Actions chimiques et utilisations
Actions pharmacologiques
Utilisations thérapeutiques
Agents du système nerveux central
Psychoanaleptiques
Tranquillisants
Neuroleptiques
Neuroleptiques : Questions médicales fréquentes
Diagnostic
5
Troubles psychotiques
Évaluation clinique
Schizophrénie
Symptômes psychotiques
Trouble bipolaire
Antipsychotiques
Évaluation de l'efficacité
Symptômes psychotiques
Tests sanguins
Évaluation psychiatrique
Symptômes
5
Hallucinations
Agitation psychomotrice
Symptômes extrapyramidaux
Effets secondaires
Variabilité des symptômes
Réponse au traitement
Cognition
Troubles de la mémoire
Prévention
5
Prévention des troubles
Soutien psychologique
Stress
Exacerbation des symptômes
Éducation familiale
Soutien familial
Groupes de soutien
Stratégies de coping
Thérapie psychologique
Prévention des rechutes
Traitements
5
Neuroleptiques typiques
Neuroleptiques atypiques
Voie orale
Administration intramusculaire
Durée du traitement
Prévention des rechutes
Suivi médical
Effets secondaires
Sevrage
Rechute des symptômes
Complications
5
Effets secondaires
Troubles extrapyramidaux
Problèmes cardiaques
Rythme cardiaque
Syndrome malin des neuroleptiques
Hyperthermie
Gestion des effets secondaires
Ajustements de dose
Facteurs de risque
5
Facteurs de risque
Antécédents familiaux
Troubles mentaux
Psychose
Sexe
Troubles psychotiques
Facteurs environnementaux
Isolement social
{
"@context": "https://schema.org",
"@graph": [
{
"@type": "MedicalWebPage",
"name": "Neuroleptiques : Questions médicales les plus fréquentes",
"headline": "Neuroleptiques : Comprendre les symptômes, diagnostics et traitements",
"description": "Guide complet et accessible sur les Neuroleptiques : explications, diagnostics, traitements et prévention. Information médicale validée destinée aux patients.",
"datePublished": "2024-05-30",
"dateModified": "2026-08-18",
"inLanguage": "fr",
"medicalAudience": [
{
"@type": "MedicalAudience",
"name": "Grand public",
"audienceType": "Patient",
"healthCondition": {
"@type": "MedicalCondition",
"name": "Neuroleptiques"
},
"suggestedMinAge": 18,
"suggestedGender": "unisex"
},
{
"@type": "MedicalAudience",
"name": "Médecins",
"audienceType": "Physician",
"geographicArea": {
"@type": "AdministrativeArea",
"name": "France"
}
},
{
"@type": "MedicalAudience",
"name": "Chercheurs",
"audienceType": "Researcher",
"geographicArea": {
"@type": "AdministrativeArea",
"name": "International"
}
}
],
"reviewedBy": {
"@type": "Person",
"name": "Dr Olivier Menir",
"jobTitle": "Expert en Médecine",
"description": "Expert en Médecine, Optimisation des Parcours de Soins et Révision Médicale",
"url": "/static/pages/docteur-olivier-menir.html",
"alumniOf": {
"@type": "EducationalOrganization",
"name": "Université Paris Descartes"
}
},
"isPartOf": {
"@type": "MedicalWebPage",
"name": "Tranquillisants",
"url": "https://questionsmedicales.fr/mesh/D014149",
"about": {
"@type": "MedicalCondition",
"name": "Tranquillisants",
"code": {
"@type": "MedicalCode",
"code": "D014149",
"codingSystem": "MeSH"
},
"identifier": {
"@type": "PropertyValue",
"propertyID": "MeSH Tree",
"value": "D27.505.954.427.700.872"
}
}
},
"about": {
"@type": "MedicalCondition",
"name": "Neuroleptiques",
"alternateName": "Antipsychotic Agents",
"code": {
"@type": "MedicalCode",
"code": "D014150",
"codingSystem": "MeSH"
}
},
"author": [
{
"@type": "Person",
"name": "Mark Suett",
"url": "https://questionsmedicales.fr/author/Mark%20Suett",
"affiliation": {
"@type": "Organization",
"name": "Global Medical Affairs, Teva UK Limited, Harlow, UK."
}
},
{
"@type": "Person",
"name": "Daniel Greer",
"url": "https://questionsmedicales.fr/author/Daniel%20Greer",
"affiliation": {
"@type": "Organization",
"name": "Rutgers Ernest Mario School of Pharmacy, 160 Frelinghuysen Rd, 08854, Piscataway, NJ, USA. dan.greer@pharmacy.rutgers.edu."
}
},
{
"@type": "Person",
"name": "Jurjen J Luykx",
"url": "https://questionsmedicales.fr/author/Jurjen%20J%20Luykx",
"affiliation": {
"@type": "Organization",
"name": "Universitair Medisch Centrum Utrecht, Hersencentrum, afd. Psychiatrie, Utrecht."
}
},
{
"@type": "Person",
"name": "Kelli R Franzenburg",
"url": "https://questionsmedicales.fr/author/Kelli%20R%20Franzenburg",
"affiliation": {
"@type": "Organization",
"name": "Global Medical Affairs, Teva Branded Pharmaceutical Products R&D, Inc., West Chester, PA, USA."
}
},
{
"@type": "Person",
"name": "Lorena Dima",
"url": "https://questionsmedicales.fr/author/Lorena%20Dima",
"affiliation": {
"@type": "Organization",
"name": "Department of Fundamental Disciplines and Clinical Prevention, Faculty of Medicine, Transilvania University of Brasov, Nicolae Balcescu Str 59, 500019, Brașov, Romania."
}
}
],
"citation": [
{
"@type": "ScholarlyArticle",
"name": "Antipsychotic Drug Reduction through the Implementation of a Neurologically Oriented, Interdisciplinary Psycho-Diagnostic and Antipsychotic Stewardship Program.",
"datePublished": "2023-09-25",
"url": "https://questionsmedicales.fr/article/37770012",
"identifier": {
"@type": "PropertyValue",
"propertyID": "DOI",
"value": "10.1016/j.jamda.2023.08.025"
}
},
{
"@type": "ScholarlyArticle",
"name": "Metabolic effects of atypical antipsychotics: Molecular targets.",
"datePublished": "2023-10-22",
"url": "https://questionsmedicales.fr/article/37866818",
"identifier": {
"@type": "PropertyValue",
"propertyID": "DOI",
"value": "10.1111/jne.13347"
}
},
{
"@type": "ScholarlyArticle",
"name": "Comparative Effectiveness of Antipsychotics in Patients With Schizophrenia Spectrum Disorder.",
"datePublished": "2024-10-01",
"url": "https://questionsmedicales.fr/article/39382894",
"identifier": {
"@type": "PropertyValue",
"propertyID": "DOI",
"value": "10.1001/jamanetworkopen.2024.38358"
}
},
{
"@type": "ScholarlyArticle",
"name": "Effect of long-term use of antipsychotics on the ventricular repolarization index.",
"datePublished": "2024-07-16",
"url": "https://questionsmedicales.fr/article/39014414",
"identifier": {
"@type": "PropertyValue",
"propertyID": "DOI",
"value": "10.1186/s12888-024-05947-1"
}
},
{
"@type": "ScholarlyArticle",
"name": "Staffing and Antipsychotic Medication Use in Nursing Homes and Neighborhood Deprivation.",
"datePublished": "2024-04-01",
"url": "https://questionsmedicales.fr/article/38656575",
"identifier": {
"@type": "PropertyValue",
"propertyID": "DOI",
"value": "10.1001/jamanetworkopen.2024.8322"
}
}
],
"breadcrumb": {
"@type": "BreadcrumbList",
"itemListElement": [
{
"@type": "ListItem",
"position": 1,
"name": "questionsmedicales.fr",
"item": "https://questionsmedicales.fr"
},
{
"@type": "ListItem",
"position": 2,
"name": "Actions chimiques et utilisations",
"item": "https://questionsmedicales.fr/mesh/D020164"
},
{
"@type": "ListItem",
"position": 3,
"name": "Actions pharmacologiques",
"item": "https://questionsmedicales.fr/mesh/D020228"
},
{
"@type": "ListItem",
"position": 4,
"name": "Utilisations thérapeutiques",
"item": "https://questionsmedicales.fr/mesh/D045506"
},
{
"@type": "ListItem",
"position": 5,
"name": "Agents du système nerveux central",
"item": "https://questionsmedicales.fr/mesh/D002491"
},
{
"@type": "ListItem",
"position": 6,
"name": "Psychoanaleptiques",
"item": "https://questionsmedicales.fr/mesh/D011619"
},
{
"@type": "ListItem",
"position": 7,
"name": "Tranquillisants",
"item": "https://questionsmedicales.fr/mesh/D014149"
},
{
"@type": "ListItem",
"position": 8,
"name": "Neuroleptiques",
"item": "https://questionsmedicales.fr/mesh/D014150"
}
]
}
},
{
"@type": "MedicalWebPage",
"name": "Article complet : Neuroleptiques - Questions et réponses",
"headline": "Questions et réponses médicales fréquentes sur Neuroleptiques",
"description": "Une compilation de questions et réponses structurées, validées par des experts médicaux.",
"datePublished": "2026-09-01",
"inLanguage": "fr",
"hasPart": [
{
"@type": "MedicalWebPage",
"name": "Diagnostic",
"headline": "Diagnostic sur Neuroleptiques",
"description": "Comment diagnostiquer un trouble psychotique ?\nQuels critères sont utilisés pour la schizophrénie ?\nLes neuroleptiques sont-ils utilisés pour d'autres troubles ?\nComment évaluer l'efficacité des neuroleptiques ?\nQuels tests sont recommandés avant traitement ?",
"url": "https://questionsmedicales.fr/mesh/D014150#section-diagnostic"
},
{
"@type": "MedicalWebPage",
"name": "Symptômes",
"headline": "Symptômes sur Neuroleptiques",
"description": "Quels sont les symptômes traités par les neuroleptiques ?\nLes neuroleptiques soulagent-ils l'anxiété ?\nPeuvent-ils provoquer des symptômes extrapyramidaux ?\nComment les symptômes varient-ils selon les patients ?\nLes neuroleptiques affectent-ils la cognition ?",
"url": "https://questionsmedicales.fr/mesh/D014150#section-symptômes"
},
{
"@type": "MedicalWebPage",
"name": "Prévention",
"headline": "Prévention sur Neuroleptiques",
"description": "Comment prévenir les troubles psychotiques ?\nLe stress peut-il déclencher des symptômes ?\nL'éducation familiale aide-t-elle ?\nLes groupes de soutien sont-ils bénéfiques ?\nLa thérapie peut-elle prévenir les rechutes ?",
"url": "https://questionsmedicales.fr/mesh/D014150#section-prévention"
},
{
"@type": "MedicalWebPage",
"name": "Traitements",
"headline": "Traitements sur Neuroleptiques",
"description": "Quels types de neuroleptiques existent ?\nComment sont administrés les neuroleptiques ?\nQuelle est la durée du traitement ?\nLes neuroleptiques nécessitent-ils un suivi médical ?\nPeut-on arrêter les neuroleptiques brusquement ?",
"url": "https://questionsmedicales.fr/mesh/D014150#section-traitements"
},
{
"@type": "MedicalWebPage",
"name": "Complications",
"headline": "Complications sur Neuroleptiques",
"description": "Quels sont les effets secondaires courants des neuroleptiques ?\nLes neuroleptiques peuvent-ils causer des problèmes cardiaques ?\nQu'est-ce que le syndrome malin des neuroleptiques ?\nComment gérer les effets secondaires ?\nLes neuroleptiques augmentent-ils le risque de diabète ?",
"url": "https://questionsmedicales.fr/mesh/D014150#section-complications"
},
{
"@type": "MedicalWebPage",
"name": "Facteurs de risque",
"headline": "Facteurs de risque sur Neuroleptiques",
"description": "Quels sont les facteurs de risque pour les troubles psychotiques ?\nL'âge influence-t-il le risque de troubles psychotiques ?\nLes troubles mentaux augmentent-ils le risque ?\nLe sexe joue-t-il un rôle dans le risque ?\nLes facteurs environnementaux influencent-ils le risque ?",
"url": "https://questionsmedicales.fr/mesh/D014150#section-facteurs de risque"
}
]
},
{
"@type": "FAQPage",
"mainEntity": [
{
"@type": "Question",
"name": "Comment diagnostiquer un trouble psychotique ?",
"position": 1,
"acceptedAnswer": {
"@type": "Answer",
"text": "Le diagnostic repose sur l'évaluation clinique, les antécédents médicaux et des tests psychologiques."
}
},
{
"@type": "Question",
"name": "Quels critères sont utilisés pour la schizophrénie ?",
"position": 2,
"acceptedAnswer": {
"@type": "Answer",
"text": "Les critères incluent des symptômes tels que hallucinations, délires et désorganisation de la pensée."
}
},
{
"@type": "Question",
"name": "Les neuroleptiques sont-ils utilisés pour d'autres troubles ?",
"position": 3,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, ils peuvent être utilisés pour le trouble bipolaire et certains troubles de l'humeur."
}
},
{
"@type": "Question",
"name": "Comment évaluer l'efficacité des neuroleptiques ?",
"position": 4,
"acceptedAnswer": {
"@type": "Answer",
"text": "L'efficacité est évaluée par la réduction des symptômes et l'amélioration du fonctionnement quotidien."
}
},
{
"@type": "Question",
"name": "Quels tests sont recommandés avant traitement ?",
"position": 5,
"acceptedAnswer": {
"@type": "Answer",
"text": "Des tests sanguins et une évaluation psychiatrique sont souvent recommandés."
}
},
{
"@type": "Question",
"name": "Quels sont les symptômes traités par les neuroleptiques ?",
"position": 6,
"acceptedAnswer": {
"@type": "Answer",
"text": "Ils traitent des symptômes tels que hallucinations, délires et agitation psychomotrice."
}
},
{
"@type": "Question",
"name": "Les neuroleptiques soulagent-ils l'anxiété ?",
"position": 7,
"acceptedAnswer": {
"@type": "Answer",
"text": "Certains neuroleptiques peuvent réduire l'anxiété, mais ce n'est pas leur usage principal."
}
},
{
"@type": "Question",
"name": "Peuvent-ils provoquer des symptômes extrapyramidaux ?",
"position": 8,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, certains neuroleptiques peuvent entraîner des symptômes extrapyramidaux comme des tremblements."
}
},
{
"@type": "Question",
"name": "Comment les symptômes varient-ils selon les patients ?",
"position": 9,
"acceptedAnswer": {
"@type": "Answer",
"text": "Les symptômes peuvent varier en fonction de la gravité du trouble et de la réponse au traitement."
}
},
{
"@type": "Question",
"name": "Les neuroleptiques affectent-ils la cognition ?",
"position": 10,
"acceptedAnswer": {
"@type": "Answer",
"text": "Ils peuvent affecter la cognition, entraînant des troubles de la mémoire ou de l'attention."
}
},
{
"@type": "Question",
"name": "Comment prévenir les troubles psychotiques ?",
"position": 11,
"acceptedAnswer": {
"@type": "Answer",
"text": "La prévention inclut la détection précoce, le soutien psychologique et l'éducation sur la santé mentale."
}
},
{
"@type": "Question",
"name": "Le stress peut-il déclencher des symptômes ?",
"position": 12,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, le stress peut exacerber les symptômes chez les personnes prédisposées aux troubles psychotiques."
}
},
{
"@type": "Question",
"name": "L'éducation familiale aide-t-elle ?",
"position": 13,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, l'éducation des familles sur les troubles psychotiques peut améliorer le soutien et la compréhension."
}
},
{
"@type": "Question",
"name": "Les groupes de soutien sont-ils bénéfiques ?",
"position": 14,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, les groupes de soutien offrent un espace pour partager des expériences et des stratégies de coping."
}
},
{
"@type": "Question",
"name": "La thérapie peut-elle prévenir les rechutes ?",
"position": 15,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, la thérapie psychologique peut aider à gérer les symptômes et prévenir les rechutes."
}
},
{
"@type": "Question",
"name": "Quels types de neuroleptiques existent ?",
"position": 16,
"acceptedAnswer": {
"@type": "Answer",
"text": "Il existe des neuroleptiques typiques et atypiques, chacun ayant des mécanismes d'action différents."
}
},
{
"@type": "Question",
"name": "Comment sont administrés les neuroleptiques ?",
"position": 17,
"acceptedAnswer": {
"@type": "Answer",
"text": "Ils peuvent être administrés par voie orale, intramusculaire ou sous forme de depot."
}
},
{
"@type": "Question",
"name": "Quelle est la durée du traitement ?",
"position": 18,
"acceptedAnswer": {
"@type": "Answer",
"text": "La durée dépend du diagnostic, mais un traitement prolongé est souvent nécessaire pour prévenir les rechutes."
}
},
{
"@type": "Question",
"name": "Les neuroleptiques nécessitent-ils un suivi médical ?",
"position": 19,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, un suivi régulier est essentiel pour ajuster le traitement et surveiller les effets secondaires."
}
},
{
"@type": "Question",
"name": "Peut-on arrêter les neuroleptiques brusquement ?",
"position": 20,
"acceptedAnswer": {
"@type": "Answer",
"text": "Non, l'arrêt brusque peut entraîner des symptômes de sevrage et une rechute des symptômes."
}
},
{
"@type": "Question",
"name": "Quels sont les effets secondaires courants des neuroleptiques ?",
"position": 21,
"acceptedAnswer": {
"@type": "Answer",
"text": "Les effets secondaires incluent la somnolence, la prise de poids et les troubles extrapyramidaux."
}
},
{
"@type": "Question",
"name": "Les neuroleptiques peuvent-ils causer des problèmes cardiaques ?",
"position": 22,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, certains neuroleptiques peuvent augmenter le risque de troubles du rythme cardiaque."
}
},
{
"@type": "Question",
"name": "Qu'est-ce que le syndrome malin des neuroleptiques ?",
"position": 23,
"acceptedAnswer": {
"@type": "Answer",
"text": "C'est une complication rare mais grave, caractérisée par une hyperthermie et une rigidité musculaire."
}
},
{
"@type": "Question",
"name": "Comment gérer les effets secondaires ?",
"position": 24,
"acceptedAnswer": {
"@type": "Answer",
"text": "La gestion peut inclure des ajustements de dose, des médicaments supplémentaires ou des changements de traitement."
}
},
{
"@type": "Question",
"name": "Les neuroleptiques augmentent-ils le risque de diabète ?",
"position": 25,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, certains neuroleptiques, en particulier les atypiques, peuvent augmenter le risque de diabète."
}
},
{
"@type": "Question",
"name": "Quels sont les facteurs de risque pour les troubles psychotiques ?",
"position": 26,
"acceptedAnswer": {
"@type": "Answer",
"text": "Les facteurs incluent des antécédents familiaux, des traumatismes et des abus de substances."
}
},
{
"@type": "Question",
"name": "L'âge influence-t-il le risque de troubles psychotiques ?",
"position": 27,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, le risque est plus élevé chez les jeunes adultes, généralement entre 18 et 25 ans."
}
},
{
"@type": "Question",
"name": "Les troubles mentaux augmentent-ils le risque ?",
"position": 28,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, les personnes ayant des antécédents de troubles mentaux sont à risque accru de psychose."
}
},
{
"@type": "Question",
"name": "Le sexe joue-t-il un rôle dans le risque ?",
"position": 29,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, les hommes sont généralement plus à risque de développer des troubles psychotiques que les femmes."
}
},
{
"@type": "Question",
"name": "Les facteurs environnementaux influencent-ils le risque ?",
"position": 30,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, des facteurs comme le stress chronique et l'isolement social peuvent augmenter le risque."
}
}
]
}
]
}
Expert en Médecine, Optimisation des Parcours de Soins et Révision Médicale
Validation scientifique effectuée le 18/08/2026
Contenu vérifié selon les dernières recommandations médicales
3 publications dans cette catégorie
Affiliations :
Global Medical Affairs, Teva UK Limited, Harlow, UK.
Publications dans "Neuroleptiques" :
3 publications dans cette catégorie
Affiliations :
Rutgers Ernest Mario School of Pharmacy, 160 Frelinghuysen Rd, 08854, Piscataway, NJ, USA. dan.greer@pharmacy.rutgers.edu.
Publications dans "Neuroleptiques" :
2 publications dans cette catégorie
Affiliations :
Universitair Medisch Centrum Utrecht, Hersencentrum, afd. Psychiatrie, Utrecht.
Contact: J.J. Luykx (j.luykx@umcutrecht.nl).
Publications dans "Neuroleptiques" :
2 publications dans cette catégorie
Affiliations :
Global Medical Affairs, Teva Branded Pharmaceutical Products R&D, Inc., West Chester, PA, USA.
Publications dans "Neuroleptiques" :
2 publications dans cette catégorie
Affiliations :
Department of Fundamental Disciplines and Clinical Prevention, Faculty of Medicine, Transilvania University of Brasov, Nicolae Balcescu Str 59, 500019, Brașov, Romania.
Publications dans "Neuroleptiques" :
2 publications dans cette catégorie
Affiliations :
Department of Child and Adolescent Psychiatry, Charite Universitaetsmedizin, Augustenburger Platz 1, 13353, Berlin, Germany.
Department of Psychiatry and Molecular Medicine, Donald and Barbara Zucker School of Medicine at Hofstra/Northwell, Hempstead, NY, USA.
Department of Psychiatry, Zucker Hillside Hospital, Northwell Health System, Glen Oaks, NY, USA.
Publications dans "Neuroleptiques" :
2 publications dans cette catégorie
Affiliations :
Global Health Economics and Outcomes Research, Teva Branded Pharmaceutical Products R&D, Inc, West Chester, PA, USA.
Publications dans "Neuroleptiques" :
2 publications dans cette catégorie
Affiliations :
Department of Psychiatry, The Zucker Hillside Hospital, Northwell Health, Glen Oaks, NY, USA.
Department of Psychiatry and Molecular Medicine, Donald and Barbara Zucker School of Medicine at Hofstra/Northwell, Hempstead, NY, USA.
Institute of Behavioral Science, Feinstein Institutes for Medical Research, Manhasset, NY, USA.
Publications dans "Neuroleptiques" :
2 publications dans cette catégorie
Affiliations :
Department of General Psychiatry, Taoyuan Psychiatric Center, Taoyuan, Taiwan.
Publications dans "Neuroleptiques" :
2 publications dans cette catégorie
Affiliations :
Department of Psychiatry, University Medical Center Groningen (UMCG), Groningen, The Netherlands.
Publications dans "Neuroleptiques" :
2 publications dans cette catégorie
Affiliations :
Department of Psychiatry, University of California, San Diego, California, USA.
Publications dans "Neuroleptiques" :
2 publications dans cette catégorie
Affiliations :
Department of Psychiatry, University Medical Center Groningen, University of Groningen.
Publications dans "Neuroleptiques" :
1 publication dans cette catégorie
Affiliations :
Department of Pharmacology, SRM Medical College Hospital and Research Centre, SRM Institute of Science and Technology, SRM nagar, Kanchipuram, Chennai, India.
Publications dans "Neuroleptiques" :
1 publication dans cette catégorie
Affiliations :
Department of Pharmacology, SRM Medical College Hospital and Research Centre, SRM Institute of Science and Technology, SRM nagar, Kanchipuram, Chennai, India.
Publications dans "Neuroleptiques" :
1 publication dans cette catégorie
Affiliations :
Ramanbhai Patel College of Pharmacy, Charotar University of Science and Technology, CHARUSAT-Campus, Changa-388421, Anand, Gujarat, India.
Publications dans "Neuroleptiques" :
1 publication dans cette catégorie
Affiliations :
Ramanbhai Patel College of Pharmacy, Charotar University of Science and Technology, CHARUSAT-Campus, Changa-388421, Anand, Gujarat, India.
Publications dans "Neuroleptiques" :
1 publication dans cette catégorie
Affiliations :
Ramanbhai Patel College of Pharmacy, Charotar University of Science and Technology, CHARUSAT-Campus, Changa-388421, Anand, Gujarat, India.
Publications dans "Neuroleptiques" :
1 publication dans cette catégorie
Affiliations :
Ramanbhai Patel College of Pharmacy, Charotar University of Science and Technology, CHARUSAT-Campus, Changa-388421, Anand, Gujarat, India.
Publications dans "Neuroleptiques" :
1 publication dans cette catégorie
Affiliations :
North Carolina State University, North Carolina, USA.
Publications dans "Neuroleptiques" :
1 publication dans cette catégorie
Affiliations :
Department of Psychiatry and Behavioral Health, Greenwich Hospital, Greenwich, Connecticut, USA.
Department of Psychiatry, Yale School of Medicine, New Haven, Connecticut, USA.
Publications dans "Neuroleptiques" :
Antipsychotic utilization in skilled nursing facilities (SNFs) is a major focus of regulatory compliance and a key theme in resident care. This created opportunities for innovations in clinical care o...
Atypical antipsychotics (AAPs) are commonly prescribed drugs in the treatment of schizophrenia, bipolar disorder and other mental diseases with psychotic traits. Although the use of AAPs is associated...
Antipsychotics are the cornerstone of maintenance treatment in schizophrenia spectrum disorders, but it is unclear which agents should be prioritized by prescribers....
To investigate the clinical effectiveness of antipsychotics, including recent market entries, in comparison with oral olanzapine in relapse and treatment failure prevention among individuals with schi...
This comparative effectiveness research study with a within-individual analysis included data from Swedish health care registers of inpatient and specialized outpatient care, sickness absence, and dis...
Specific antipsychotics....
The risks for psychosis relapse hospitalization and treatment failure (psychiatric hospitalization, death, or change in an antipsychotic medication) were adjusted for the temporal order of treatments,...
Among the full cohort of 131 476 individuals, the mean (SD) age of the study cohort was 45.7 (16.2) years (70 054 men [53.3%]). During a median follow-up of 12.0 years [IQR, 5.2-16.0 years], 48.5% of ...
This comparative effectiveness research study demonstrated large differences in the risk of relapse and treatment failure among specific antipsychotic treatments. The findings contradict the widely he...
The risk of arrhythmia is usually assessed by the length of the corrected QT interval (QTc) when patients use antipsychotics. Prolonged QTc intervals are thought to increase the probability of maligna...
To investigate the changes in ventricular repolarization indices and the occurrence of arrhythmias in patients who have been using antipsychotic drugs for a long time, to compare the changes in iCEBc ...
Patients with schizophrenia who had been hospitalized for more than 4 years and who were receiving atypical antipsychotics underwent a 12-lead synchronized electrocardiogram (ECG) every 2-4 weeks. The...
The patients had been treated with antipsychotic medication for 4 years, and the duration of the QRS wave was longer in males than in females. TpTe, TpTe/QRS, TpTe/QT, TpTe/QTc, iCEB, and iCEBc increa...
After long-term use of antipsychotics, the ventricular repolarization index gradually increased with time. The new ventricular repolarization indices iCEB and iCEBc were more sensitive than the QTc at...
Inappropriate use of antipsychotic medications in nursing homes is a growing public health concern. Residents exposed to higher levels of socioeconomic deprivation in the area around a nursing home ma...
To evaluate whether reported inappropriate antipsychotic medication use differs in severely and less severely deprived neighborhoods, and whether these differences are modified by higher levels of tot...
This was a cross-sectional analysis of a national sample of nursing homes that linked across 3 national large-scale data sets for the year 2019. Analyses were conducted between April and June 2023....
Neighborhood deprivation status (severe vs less severe) and total staffing hours (registered nurse, licensed practical nurse, certified nursing assistant)....
This study estimated the association between neighborhood deprivation and the percentage of long-stay residents who received an antipsychotic medication inappropriately in the nursing home at least on...
This study included 10 966 nursing homes (1867 [17.0%] in severely deprived neighborhoods and 9099 [83.0%] in less deprived neighborhoods). Unadjusted inappropriate antipsychotic medication use was gr...
These findings suggest that levels of staffing modify disparities seen in inappropriate antipsychotic medication use among nursing homes located in severely deprived neighborhoods compared with nursin...
Pharmacists have a contribution to make in improving optimising medication use for people on antipsychotic medication. The rates of prescribing antipsychotics have increased in England with an 18% ris...
In this paper we discuss the risks and benefits of discontinuing antipsychotic medication within one year after remission of a first episode of psychosis. We start with a fictional case report of a 21...
The American Psychiatric Association guidelines for the treatment of patients with schizophrenia state that the utility of antipsychotic therapeutic drug monitoring (TDM) remains unclear, except for c...
Patients with antipsychotic blood levels drawn between May 1, 2021 and January 31, 2023 were invited to consent for retrospective chart data analysis to determine the influence of antipsychotic blood ...
A total of 135 antipsychotic levels from 40 inpatients were analyzed. Approximately 48% of the levels were appropriately drawn, whereas 52% were inappropriately drawn. Clozapine had the highest TDM ra...
Most antipsychotic drug levels were inappropriately drawn, emphasizing the complexity and potential for errors in TDM. Although more patients were prescribed risperidone, clozapine had the highest TDM...
Medication shortages in The Netherlands are getting worse since 2019, with numbers increasing every year. In September 2023, during our work in a psychiatric outpatient clinic, we were confronted with...
According to this study: Use of antipsychotics in patients with dementia is associated with an increased risk of a wide range of serious adverse outcomes, particularly soon after the initiation of tre...